<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161889">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00991029</url>
  </required_header>
  <id_info>
    <org_study_id>1U01S062835-01A1</org_study_id>
    <nct_id>NCT00991029</nct_id>
  </id_info>
  <brief_title>Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial</brief_title>
  <acronym>POINT</acronym>
  <official_title>Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neurological Emergencies Treatment Trials Network (NETT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused
      by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic
      stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor
      ischemic strokes (with an NIH Stroke Scale [NIHSS] score less than or equal to 3).

      TIAs are common [25], and are often harbingers of disabling strokes. Approximately
      250,000-350,000 TIAs are diagnosed each year in the US. Given median survival of more than 8
      years [32], there are approximately 2.4 million TIA survivors. In a national survey, one in
      fifteen of those over 65 years old reported a history of TIA [33], which is equivalent to a
      prevalence of 2.3 million in older Americans. Based on the prevalence of undiagnosed
      transient neurological events, the true incidence of TIA may be twice as high as the rates
      of diagnosis [33]. Based on our review of the National Inpatient Sample for 1997-2003, there
      were an average of 200,000 hospital admissions for TIA each year, with annual charges
      climbing quickly in the period to $2.6 billion in 2003.

      Composite endpoint of new ischemic vascular events: ischemic stroke, myocardial infarction
      or ischemic vascular death at 90 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, is a
      prospective, randomized, double-blind, multicenter trial with the primary null hypothesis
      that, in patients with TIA or minor ischemic stroke treated with aspirin 50-325 mg/day,
      there is no difference in the event-free survival at 90 days in those treated with
      clopidogrel (600 mg loading dose then 75 mg/day) compared to placebo when subjects are
      randomized within 12 hours of time last known free of new ischemic symptoms.

      Its primary objective is to determine whether clopidogrel 75 mg/day by mouth after a loading
      dose of 600 mg of clopidogrel is effective in preventing major ischemic vascular events
      (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when
      initiated within 12 hours of TIA or minor ischemic stroke onset in patients receiving
      aspirin 50-325 mg/day (with a dose of 150-200 mg daily for 5 days followed by 75-100 mg
      daily strongly recommended).

      Patients over 18 years of age with high-risk TIA (defined as an ABCD2 score greater than or
      equal to 4) or minor ischemic stroke (with NIHSS less than or equal to 3) who can be treated
      within 12 hours of time last known free of new ischemic symptoms will be enrolled.

      Subjects will be randomized 1:1 (clopidogrel: placebo), controlling for clinical center. A
      study participant's eligibility will be determined by site personnel prior to accessing the
      Randomization Module in the WebDCU™, a web-enabled clinical trials management system that
      was developed by the NETT Statistics and Data Management Center (SDMC) at Medical University
      of South Carolina (MUSC).Qualified users will access the Randomization Interface and
      complete a protocol-specific eligibility checklist. If the Randomization Interface finds the
      patient to be eligible based on the information provided, a randomization number and a
      confirmatory e-mail are generated.

      Each subject is followed for 90 days from randomization; the trial will be completed in 7
      years.

      A total of 5,840 patients will be recruited. Recruitment will occur over 90 months, with a
      goal rate of 0.40 subjects/site/month for US sites, and a goal rate of 0.47
      subjects/site/month for OUS sites. Current participating sites can be found at:
      http://www.pointtrial.org/node/18.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>New ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>secondary outcomes will be evaluated, separately including risk of ischemic stroke, intracranial hemorrhage, and major hemorrhage, and the composite of the primary outcome and major hemorrhage.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5840</enrollment>
  <condition>Ischemic Attack, Transient</condition>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients assigned to clopidogrel in addition to aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned to placebo in addition to aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days</description>
    <arm_group_label>clopidogrel</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Loading dose of 8 tablets followed by one tablet daily for 89 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neurological deficit (based on history or exam) attributed to focal brain ischemia
             and EITHER:

               -  High risk TIA: Complete resolution of the deficit at the time of randomization
                  AND ABCD2 score of (greater than or equal to) 4 OR

               -  Minor ischemic stroke: residual deficit with NIHSS of (less than or equal to) 3
                  at the time of randomization

          -  Ability to randomize within 12 hours of time last known free of new ischemic
             symptoms.

          -  Head CT or MRI ruling out hemorrhage or other pathology, such as vascular
             malformation, tumor, or abscess, that could explain symptoms or contraindicate
             therapy.

          -  Ability to tolerate aspirin at a does of 50-325 mg/day.

        Exclusion Criteria

          -  Age &lt;18 years

          -  TIA symptoms limited to isolated numbness, isolated visual changes, or isolated
             dizziness/vertigo.

          -  In the judgment of the treating physician, a candidate for thrombolysis,
             endarterectomy or endovascular intervention, unless the subject declines both
             endarterectomy and endovascular intervention at the time of evaluation for
             eligibility.

          -  Receipt of any intravenous or intra-arterial thrombolysis within 1 week prior to
             index event.

          -  Gastrointestinal bleed or major surgery within 3 months prior to index event.

          -  History of nontraumatic intracranial hemorrhage.

          -  Clear indication for anticoagulation (e.g., warfarin, heparin) anticipated during the
             study period (atrial fibrillation, mechanical heart valve, deep venous thrombosis,
             pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state).

          -  Qualifying ischemic event induced by angiography or surgery.

          -  Severe non-cardiovascular comorbidity with life expectancy &lt;3 months.

          -  Contraindication to clopidogrel or aspirin.

               -  Known allergy

               -  Severe renal (serum creatinine &gt;2 mg/dL or 176.8umol/L) or hepatic insufficiency
                  (prior or concurrent diagnosis, with International Normalized Ratio (INR)&gt;1.5 or
                  any resultant complication, such as variceal bleeding, encephalopathy, or
                  icterus)

               -  Hemostatic disorder or systemic bleeding in the past 3 months

               -  Current thrombocytopenia (platelet count &lt;100 x10^9/l) or neutropenia (&lt;1
                  x10^9/l)

               -  History of drug-induced hematologic or hepatic abnormalities

          -  Anticipated requirement for long-term (&gt;7 day) non-study antiplatelet drugs (eg,
             dipyridamole, clopidogrel, ticlopidine), or Non-steroidal Anti-inflammatory Drugs
             (NSAIDs) affecting platelet function (such as prior vascular stent or arthritis).

          -  Inability to swallow medications.

          -  At risk for pregnancy: premenopausal or post menopausal woman within 12 months of
             last menses without a negative pregnancy test or not committing to adequate birth
             control (e.g., oral contraceptive, two methods of barrier birth control, or
             abstinence).

          -  Unavailability for follow-up.

          -  Signed and dated informed consent not obtained from patient.

          -  Other neurological conditions that would complicate assessment of outcomes during
             follow-up.

          -  Ongoing treatment in another study of an investigational therapy that may potentially
             interact with study drug, or treatment in such a study within the last 7 days.

          -  Previously enrolled in the POINT study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Claiborne Johnston, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas, Austin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Donald Easton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anthony S. Kim, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco Stroke Sciences Group</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Farrant, MBA BSN RN</last_name>
      <phone>415-502-7304</phone>
      <email>mary.farrant@ucsfmedctr.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ovbiagele B. Antiplatelet therapy in management of transient ischemic attack: overview and evidence-based rationale. J Emerg Med. 2008 May;34(4):389-96. doi: 10.1016/j.jemermed.2007.08.056. Epub 2008 Jan 18. Review.</citation>
    <PMID>18207691</PMID>
  </reference>
  <reference>
    <citation>Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol. 2007 Dec;6(12):1063-72. Epub 2007 Nov 13. Review.</citation>
    <PMID>17993293</PMID>
  </reference>
  <reference>
    <citation>Kernan WN, Schindler JL. Rapid intervention for TIA: a new standard emerges. Lancet Neurol. 2007 Nov;6(11):940-1.</citation>
    <PMID>17928271</PMID>
  </reference>
  <reference>
    <citation>Rothwell PM. Transient ischaemic attacks: time to wake up. Heart. 2007 Aug;93(8):893-4.</citation>
    <PMID>17639101</PMID>
  </reference>
  <reference>
    <citation>Streifler JY. Early stroke risk after a transient ischemic attack: can it be minimized? Stroke. 2008 Jun;39(6):1655-6. doi: 10.1161/STROKEAHA.107.510248. Epub 2008 Mar 27.</citation>
    <PMID>18369165</PMID>
  </reference>
  <reference>
    <citation>Dean N, Shuaib A. Transient ischaemic attacks: unstable, treatable, neglected. Lancet. 2007 Oct 20;370(9596):1398-400.</citation>
    <PMID>17928045</PMID>
  </reference>
  <reference>
    <citation>Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators.. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 2007 Nov;6(11):961-9. Epub 2007 Oct 10.</citation>
    <PMID>17931979</PMID>
  </reference>
  <reference>
    <citation>Geisler T, Zürn C, Paterok M, Göhring-Frischholz K, Bigalke B, Stellos K, Seizer P, Kraemer BF, Dippon J, May AE, Herdeg C, Gawaz M. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J. 2008 Jul;29(13):1635-43. doi: 10.1093/eurheartj/ehn212. Epub 2008 May 24.</citation>
    <PMID>18503057</PMID>
  </reference>
  <reference>
    <citation>Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP; TIMI 22 Investigators.. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis. Am Heart J. 2008 May;155(5):954-8. doi: 10.1016/j.ahj.2007.12.009. Epub 2008 Feb 19.</citation>
    <PMID>18440347</PMID>
  </reference>
  <reference>
    <citation>Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation. 2004 Mar 23;109(11):1335-8. Epub 2004 Mar 15.</citation>
    <PMID>15023882</PMID>
  </reference>
  <reference>
    <citation>Riondino S, Petrini N, Donato L, Torromeo C, Tanzilli G, Pulcinelli FM, Barillà F. Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. J Thromb Thrombolysis. 2009 Aug;28(2):151-5. doi: 10.1007/s11239-008-0254-6. Epub 2008 Jul 18.</citation>
    <PMID>18636229</PMID>
  </reference>
  <reference>
    <citation>Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K, Topol EJ; CHARISMA Investigators.. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol. 2007 Jul 24;50(4):291-5. Epub 2007 Jul 10.</citation>
    <PMID>17659194</PMID>
  </reference>
  <reference>
    <citation>Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ; Clopidogrel for the Reduction of Events During Observation Investigators.. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003 Aug 26;108(8):921-4. Epub 2003 Aug 18.</citation>
    <PMID>12925453</PMID>
  </reference>
  <reference>
    <citation>Trenk D, Hochholzer W, Frundi D, Stratz C, Valina CM, Bestehorn HP, Büttner HJ, Neumann FJ. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost. 2008 Jan;99(1):174-81. doi: 10.1160/TH07-08-0503.</citation>
    <PMID>18217151</PMID>
  </reference>
  <reference>
    <citation>Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA. 2000 Dec 13;284(22):2901-6.</citation>
    <PMID>11147987</PMID>
  </reference>
  <reference>
    <citation>Coutts SB, Eliasziw M, Hill MD, Scott JN, Subramaniam S, Buchan AM, Demchuk AM; VISION study group.. An improved scoring system for identifying patients at high early risk of stroke and functional impairment after an acute transient ischemic attack or minor stroke. Int J Stroke. 2008 Feb;3(1):3-10. doi: 10.1111/j.1747-4949.2008.00182.x.</citation>
    <PMID>18705908</PMID>
  </reference>
  <reference>
    <citation>Coutts SB, Simon JE, Eliasziw M, Sohn CH, Hill MD, Barber PA, Palumbo V, Kennedy J, Roy J, Gagnon A, Scott JN, Buchan AM, Demchuk AM. Triaging transient ischemic attack and minor stroke patients using acute magnetic resonance imaging. Ann Neurol. 2005 Jun;57(6):848-54.</citation>
    <PMID>15929051</PMID>
  </reference>
  <reference>
    <citation>Algra A, van Gijn J, Halkes PH, Kappelle LJ, Koudstaal PJ; ESPRIT Study Group.. Interpretation of ESPRIT in the FASTER trial. Lancet Neurol. 2008 Mar;7(3):198-9; author reply 199. doi: 10.1016/S1474-4422(08)70030-9.</citation>
    <PMID>18275919</PMID>
  </reference>
  <reference>
    <citation>Lavallée PC, Meseguer E, Abboud H, Cabrejo L, Olivot JM, Simon O, Mazighi M, Nifle C, Niclot P, Lapergue B, Klein IF, Brochet E, Steg PG, Lesèche G, Labreuche J, Touboul PJ, Amarenco P. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol. 2007 Nov;6(11):953-60.</citation>
    <PMID>17928270</PMID>
  </reference>
  <reference>
    <citation>Luengo-Fernandez R, Gray AM, Rothwell PM. Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison. Lancet Neurol. 2009 Mar;8(3):235-43. doi: 10.1016/S1474-4422(09)70019-5. Epub 2009 Feb 4.</citation>
    <PMID>19200786</PMID>
  </reference>
  <reference>
    <citation>Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group.. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008 Sep 18;359(12):1225-37. doi: 10.1056/NEJMoa0804593. Epub 2008 Aug 27.</citation>
    <PMID>18753639</PMID>
  </reference>
  <reference>
    <citation>Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group.. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008 Sep 18;359(12):1238-51. doi: 10.1056/NEJMoa0805002. Epub 2008 Aug 27.</citation>
    <PMID>18753638</PMID>
  </reference>
  <reference>
    <citation>Brown RD Jr, Petty GW, O'Fallon WM, Wiebers DO, Whisnant JP. Incidence of transient ischemic attack in Rochester, Minnesota, 1985-1989. Stroke. 1998 Oct;29(10):2109-13.</citation>
    <PMID>9756590</PMID>
  </reference>
  <reference>
    <citation>Kissela B, Broderick J, Woo D, Kothari R, Miller R, Khoury J, Brott T, Pancioli A, Jauch E, Gebel J, Shukla R, Alwell K, Tomsick T. Greater Cincinnati/Northern Kentucky Stroke Study: volume of first-ever ischemic stroke among blacks in a population-based study. Stroke. 2001 Jun;32(6):1285-90.</citation>
    <PMID>11387488</PMID>
  </reference>
  <reference>
    <citation>Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke. 1999 Dec;30(12):2523-8.</citation>
    <PMID>10582972</PMID>
  </reference>
  <reference>
    <citation>Kleindorfer D, Panagos P, Pancioli A, Khoury J, Kissela B, Woo D, Schneider A, Alwell K, Jauch E, Miller R, Moomaw C, Shukla R, Broderick JP. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke. 2005 Apr;36(4):720-3. Epub 2005 Feb 24.</citation>
    <PMID>15731465</PMID>
  </reference>
  <reference>
    <citation>Edlow JA, Kim S, Pelletier AJ, Camargo CA Jr. National study on emergency department visits for transient ischemic attack, 1992-2001. Acad Emerg Med. 2006 Jun;13(6):666-72. Epub 2006 Apr 11.</citation>
    <PMID>16609106</PMID>
  </reference>
  <reference>
    <citation>Howard G, Toole JF, Frye-Pierson J, Hinshelwood LC. Factors influencing the survival of 451 transient ischemic attack patients. Stroke. 1987 May-Jun;18(3):552-7.</citation>
    <PMID>3590245</PMID>
  </reference>
  <reference>
    <citation>Shah KH, Kleckner K, Edlow JA. Short-term prognosis of stroke among patients diagnosed in the emergency department with a transient ischemic attack. Ann Emerg Med. 2008 Mar;51(3):316-23. doi: 10.1016/j.annemergmed.2007.08.016. Epub 2007 Oct 25. Review. Erratum in: Ann Emerg Med. 2008 Jun;51(6):774.</citation>
    <PMID>18282526</PMID>
  </reference>
  <reference>
    <citation>Wu CM, McLaughlin K, Lorenzetti DL, Hill MD, Manns BJ, Ghali WA. Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med. 2007 Dec 10;167(22):2417-22. Review.</citation>
    <PMID>18071162</PMID>
  </reference>
  <reference>
    <citation>Gladstone DJ, Kapral MK, Fang J, Laupacis A, Tu JV. Management and outcomes of transient ischemic attacks in Ontario. CMAJ. 2004 Mar 30;170(7):1099-104.</citation>
    <PMID>15051693</PMID>
  </reference>
  <reference>
    <citation>Lisabeth LD, Ireland JK, Risser JM, Brown DL, Smith MA, Garcia NM, Morgenstern LB. Stroke risk after transient ischemic attack in a population-based setting. Stroke. 2004 Aug;35(8):1842-6. Epub 2004 Jun 10.</citation>
    <PMID>15192239</PMID>
  </reference>
  <reference>
    <citation>Eliasziw M, Kennedy J, Hill MD, Buchan AM, Barnett HJ; North American Symptomatic Carotid Endarterectomy Trial Group.. Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease. CMAJ. 2004 Mar 30;170(7):1105-9.</citation>
    <PMID>15051694</PMID>
  </reference>
  <reference>
    <citation>Hill MD, Yiannakoulias N, Jeerakathil T, Tu JV, Svenson LW, Schopflocher DP. The high risk of stroke immediately after transient ischemic attack: a population-based study. Neurology. 2004 Jun 8;62(11):2015-20.</citation>
    <PMID>15184607</PMID>
  </reference>
  <reference>
    <citation>Rothwell PM, Giles MF, Flossmann E, Lovelock CE, Redgrave JN, Warlow CP, Mehta Z. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet. 2005 Jul 2-8;366(9479):29-36.</citation>
    <PMID>15993230</PMID>
  </reference>
  <reference>
    <citation>Lovett JK, Dennis MS, Sandercock PA, Bamford J, Warlow CP, Rothwell PM. Very early risk of stroke after a first transient ischemic attack. Stroke. 2003 Aug;34(8):e138-40. Epub 2003 Jul 10.</citation>
    <PMID>12855835</PMID>
  </reference>
  <reference>
    <citation>Rao SV, Ohman EM, Granger CB, Armstrong PW, Gibler WB, Christenson RH, Hasselblad V, Stebbins A, McNulty S, Newby LK. Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. Am J Cardiol. 2003 Apr 15;91(8):936-40.</citation>
    <PMID>12686331</PMID>
  </reference>
  <reference>
    <citation>Whisnant JP, Matsumoto N, Elveback LR. Transient cerebral ischemic attacks in a community. Rochester, Minnesota, 1955 through 1969. Mayo Clin Proc. 1973 Mar;48(3):194-8.</citation>
    <PMID>4690325</PMID>
  </reference>
  <reference>
    <citation>Humphrey PR, Marshall J. Transient ischemic attacks and strokes with recovery prognosis and investigation. Stroke. 1981 Nov-Dec;12(6):765-9.</citation>
    <PMID>7303066</PMID>
  </reference>
  <reference>
    <citation>Putman SF, Adams HP Jr. Usefulness of heparin in initial management of patients with recent transient ischemic attacks. Arch Neurol. 1985 Oct;42(10):960-2.</citation>
    <PMID>4038103</PMID>
  </reference>
  <reference>
    <citation>Biller J, Bruno A, Adams HP Jr, Godersky JC, Loftus CM, Mitchell VL, Banwart KJ, Jones MP. A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study. Stroke. 1989 Apr;20(4):441-7.</citation>
    <PMID>2648650</PMID>
  </reference>
  <reference>
    <citation>Dennis M, Bamford J, Sandercock P, Warlow C. Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project. Stroke. 1990 Jun;21(6):848-53.</citation>
    <PMID>2349586</PMID>
  </reference>
  <reference>
    <citation>Coull AJ, Lovett JK, Rothwell PM; Oxford Vascular Study.. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ. 2004 Feb 7;328(7435):326. Epub 2004 Jan 26.</citation>
    <PMID>14744823</PMID>
  </reference>
  <reference>
    <citation>Daffertshofer M, Mielke O, Pullwitt A, Felsenstein M, Hennerici M. Transient ischemic attacks are more than &quot;ministrokes&quot;. Stroke. 2004 Nov;35(11):2453-8. Epub 2004 Oct 14.</citation>
    <PMID>15486333</PMID>
  </reference>
  <reference>
    <citation>Whitehead MA, McManus J, McAlpine C, Langhorne P. Early recurrence of cerebrovascular events after transient ischaemic attack. Stroke. 2005 Jan;36(1):1; author reply 1.</citation>
    <PMID>15618448</PMID>
  </reference>
  <reference>
    <citation>Correia M, Silva MR, Magalhães R, Guimarães L, Silva MC. Transient ischemic attacks in rural and urban northern Portugal: incidence and short-term prognosis. Stroke. 2006 Jan;37(1):50-5. Epub 2005 Dec 1.</citation>
    <PMID>16322498</PMID>
  </reference>
  <reference>
    <citation>Purroy F, Molina CA, Montaner J, Alvarez-Sabín J. Absence of usefulness of ABCD score in the early risk of stroke of transient ischemic attack patients. Stroke. 2007 Mar;38(3):855-6; author reply 857. Epub 2007 Jan 18.</citation>
    <PMID>17234986</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Johnston SC; CHANCE Investigators.. Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J. 2010 Sep;160(3):380-386.e1. doi: 10.1016/j.ahj.2010.05.017.</citation>
    <PMID>20826243</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC; CHANCE Investigators.. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 Jul 4;369(1):11-9. doi: 10.1056/NEJMoa1215340. Epub 2013 Jun 26.</citation>
    <PMID>23803136</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 18, 2016</lastchanged_date>
  <firstreceived_date>October 6, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transient Ischemic Attack</keyword>
  <keyword>TIA</keyword>
  <keyword>minor stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
